Oct 24 2025 This Week in Cardiology

The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial
https://www.medscape.com/viewarticle/prevent-calculator-best-determining-cvd-risk-insights-post-2025a1000svo
PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037
SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939
II GLP-1 Mechanism of Action in CV Disease
Analysis of SELECT Trial 10.1016/S0140-6736(25)01375-3 External Link
SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
III Statins and CAD Phenotype on CTA and Outcomes
Interactions Between Statin Use, CAD Phenotypes on CTA https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018
Statin Use for Primary Prevention of CVD https://jamanetwork.com/journals/jama/fullarticle/2795522
IV HHF Endpoints in Heart Failure Trials
The Problem with Hospitalization Endpoints in HF Trials https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.